

Dr. Dibakar Podder
Curriculum Vitae

Correspondence:

Department of Clinical Hematology and Cellular Therapies,
Tata Medical Center,
14, Main Arterial Road (E-W), DH Block, New town, Kolkata: 700160.

Current Position:

Associate Consultant
Department of Clinical Hematology and Cellular Therapies
Tata Medical Center

Areas of Interest:

Plasma cell Neoplasm, Multiple Myeloma, MGUS, MGRS, Amyloidosis
Lymphomas
Hemoglobinopathies, Aplastic Anemia, Coagulopathies
Stem Cell transplant and Cellular therapies

Education

MBBS, Agartala Government Medical College, Agartala

August 2005 — January 2010

MD (Pathology), Kasturba Medical College, Manipal, Udupi

May 2012 — May 2015

Post Doctoral Fellowship (Clinical Hematology and Stem Cell transplant), Tata Medical Center, Kolkata

February 2016 — June 2018

DM (Clinical Hematology), Medical College and Hospital, Kolkata

August 2018 — August 2021

Clinical Experience

Assistant Professor (Tripura Medical College), Tripura

September 2016 — February 2016

Junior Consultant (CNCI), Kolkata

October 2021 — February 2022

Clinical Associate (Tata Medical Center), Kolkata

March 2022 — December 2022

Junior Consultant, (Tata Medical Center), Kolkata

January 2023 — January 2024

Associate Consultant, (Tata Medical Center), Kolkata

January 2024- present

Department of Clinical Hematology and Cellular Therapies

Conference Papers:

National:

1. Pineal gland tumors- a report of two cases. NEUROPATH CME; 2014
2. Clinicopathologic and radiologic features of thymoma in 10 cases based on 2004 WHO classification- Annual Pathology conference, Goa; 2015
3. Cytopathology of mucoepidermoid carcinoma of salivary glands
4. Clinicopathological Characteristics and Outcome in Patients of Primary CNS Lymphoma Treated with Modified De-Angelis Protocol: An Audit; SOHO 2018, Houston
5. Case series of hairy cell leukemia- a rare low-grade B cell lymphoma with unusual presentation. BESHCON 2018, Kolkata
6. MPN with T lymphoblastic lymphoma associated with a novel cytogenetic abnormality- a case report: HEMATOCON 2019, Delhi
7. Safety and Efficacy of low dose thalidomide in transfusion dependent E-beta Thalassemia. BESHCON 2021, Kolkata

International

1. BK virus reactivations in patients undergoing Allogeneic stem cell transplant-an audit. APBMT 2022, Cochin
2. Efficacy and safety of Ponatinib in chronic phase CML- Real world data from a tertiary care center- HEMATOCON 2022, Kolkata
3. Clinical Characteristics and Outcome of Extranodal NK T-Cell Lymphoma Nasal Type: A Decade's Experience- SOHO 2024, Houston
4. Early Impressions With Use of BCMA-Directed Therapy: Elranatamab in Multiply Relapsed/Refractory Multiple Myeloma: A Safety and Efficacy Analysis in a Tertiary Cancer Center in India- SOHO 2024, Houston
5. A journey through understanding and managing Waldenstrom's Macroglobulinemia (WM): 13 years of Insight- EHA 2025, Milan
6. A retrospective analysis of AL-AMYLOIDOSIS in a tertiary care center in India- EHA 2025, Milan
7. Solitary plasmacytoma – a real world outcome analysis from India- EHA 2025, Milan
8. Kumar, J., Pincha, R., Radhakrishnan, V. S., Tamboli, N., Nag, A., **Podder, D.**, Chattopadhyay, D., Bhawe, S. J., Das, S., Parihar, M., Rath, A., Vinarkar, S., Mukhopadhyay, S., Chakraborty, S., Mishra, D. K., Chandy, M., & Nair, R. (2023). Safety and Efficacy of Bortezomib-Pomalidomide-Dexamethasone (VPD) As Novel Induction Therapy in Newly-Diagnosed Multiple Myeloma: Updated Data from an Ongoing Single Arm Phase-II Investigator- Initiated Clinical Trial (PRIME Study). *Blood*, 142(Supplement 1), 6713. <https://doi.org/10.1182/blood-2023-186903>
9. **Podder Dibakar**; Bhattacharyya Subhadip Pincha Rajat Sahoo Aradhana KT Baalamurugan Shinde Suchita Mundra Pallav Chattopadhyay Debranjani Ghosh Shouriyio Nag Arijit Kumar Jeevan Zameer Lateef Arun Indu Achari Rimpa Nair Reena. Clinical Characteristics and Outcome of Extranodal NK T-Cell Lymphoma Nasal Type: A Decade's Experience. *Clinical Lymphoma Myeloma and Leukemia*. 24. S230. 10.1016/S2152-2650(24)00910-8.
10. **Podder Dibakar** Patil Noopur Brahma Anupam Shewale Sundar Javed Rizwan Chattopadhyay Debranjani Ghosh Shouriyio Nag Arijit Kumar Jeevan Rath Ashish Vinarkar Sushant Parihar Mayur Mishra Deepak Chakraborty Subhosmito Nair Reena. (2024). Early Impressions With Use of BCMA-Directed Therapy: Elranatamab in Multiply Relapsed/Refractory Multiple Myeloma: A

Safety and Efficacy Analysis in a Tertiary Cancer Center in India. *Clinical Lymphoma Myeloma and Leukemia*. 24. S559. 10.1016/S2152-2650(24)01685-9.

11. Ghosh, Shouriyi Sinha Subir Chatterjee Sutapa Nag Arijit Chattopadhyay Debranjani **Podder Dibakar** Kumar Jeevan Javed Rizwan Rath Asish Mishra Deepak Vinarkar Sushant Parihar Mayur Nair Reena. Outcomes of Azacytidine-Venetoclax Th in Upfront and Relapsed/Refractory Setting in Acute Myeloid Leukemia: Real World Experience from India. *Clinical Lymphoma Myeloma and Leukemia*. 24. S171. 10.1016/S2152-2650(24)00509-3
12. Pincha Rajat Ghosh Shouriyi **Podder Dibakar** Kumar Jeevan Nag Arijit Javed Rizwan Chattopadhyay Debranjani Mishra Deepak Parihar, Mayur Nair Reena. Outcome of Autologous Stem Cell Transplantation in High-Risk Multiple Myeloma: A Single-Center Experience. *Clinical Lymphoma Myeloma and Leukemia*. 24. S241. 10.1016/S2152-2650(24)00981-9.

Publications

1. Singh M, **Podder D**, Jacoby A P, et al. (June 03, 2026) Efficacy and Safety of Bruton Tyrosine Kinase Inhibitors in Waldenström Macroglobulinemia: A Single-Center Retrospective Analysis. *Cureus* 18(6): e110182. doi:10.7759/cureus.110182
2. **Podder D**, Sonowal H, Saha S, et al. Real world data on Solitary Plasmacytoma from eastern India- highlighting favorable trends in outcome. *medRxiv*. Published online 2026. doi:[10.64898/2026.04.15.26350956](https://doi.org/10.64898/2026.04.15.26350956) (preprint)
3. Gupta V, **Podder D**, Saha S, et al. Clinico-pathologic characteristics, patterns of treatment and outcome of newly diagnosed Waldenströms Macroglobulinemia- a single center real world retrospective analysis. *medRxiv*. Published online January 1, 2026:2026.04.10.26350611. doi:[10.64898/2026.04.10.26350611](https://doi.org/10.64898/2026.04.10.26350611) (preprint)
4. **Podder, D.**, Patil, N., Ghosh, S. *et al.* Real world data on Anti BCMA bispecific antibody therapy in relapsed refractory multiple myeloma - treading on a razor edge between efficacy and safety. *Indian J Hematol Blood Transfus* (2026). <https://doi.org/10.1007/s12288-026-02381-z>
5. Shah, B., **Podder, D.**, Ghosh, S. *et al.* Real World Outcome of Primary Plasma Cell leukemia - a Retrospective Analysis from a Tertiary Care Center from Eastern India. *Indian J Hematol Blood Transfus* (2026). <https://doi.org/10.1007/s12288-026-02350-6>
6. Gupta, P., Ghosh, S., **Podder D**; Roy, S. *et al.* In Search for the Ideal All-Trans-Retinoic Acid Dose in Acute Promyelocytic Leukemia: Striking the Balance Between Drug Toxicity and Measurable Residual Disease Clearance. *Indian J Hematol Blood Transfus* (2025). <https://doi.org/10.1007/s12288-025-02230-5>
7. Nag A, Kt B, Kumar J, Ghosh S, **Podder D**, Chattopadhyay D, Saha S, Javed R, Chatterji S, Rath A, Nair R, Bharat S. Bioequivalent Letermovir Usage for Prophylaxis in Haploidentical Stem Cell Transplantation at High Risk of CMV Reactivation: A Report of Two Cases From India. *Cureus*. 2025 Apr 26;17(4):e83035. doi: 10.7759/cureus.83035. PMID: 40432636; PMCID: PMC12106792.
8. T, B.K., Ghosh, S., **Podder, D.** *et al.* Ponatinib in Chronic Myeloid Leukaemia Refractory To Multiple Tyrosine Kinase Inhibitors: Data from a Tertiary Care Centre in India. *Indian J Hematol Blood Transfus* (2025). <https://doi.org/10.1007/s12288-025-02184-8>
9. VS, R., **Podder D.**, H, M. *et al.* Primary Central Nervous System Lymphoma: Long-Term Treatment Clinicopathological Characteristics and Outcome in Patients of Primary CNS Lymphoma Treated

with Modified De-Angelis Protocol: An Audit SOHO 2018 DOI: 10.1016/j.clml.2018.07.210 Outcomes and Cost-Analysis from a Retrospective Study of High-Dose Methotrexate Based Chemoimmunotherapy and Reduced Dose Radiation Therapy Approach. *Indian J Hematol Blood Transfus*(2021). <https://doi.org/10.1007/s12288-021-01444-7>

10. Shinde S, Guntiboina VA, Nag A, **Podder D**, Chattopadhyay D, Kumar J, Bhave S, Mishra DK, Chandy M, Nair R. Melphalan-associated encephalopathy following autologous stem cell transplant: a transplanters nightmare! *Blood Cell Ther.* 2024 Mar 15;7(2):33-36. doi: 10.31547/bct-2023-025
11. Nayak Deepak M, Manohar Chethan, **Podder Dibakar**, Kakkur Richa. EDTA- Induced lymphoid clumping in follicular lymphoma- a case report. *Int j clin surg adv* 2013; 1(2):12-15
12. **Podder D**, Monappa V, Shetty P. Soft tissue chondroma: a rare tumor presenting as cutaneous nodule. *Our Dermatol Online.* 2014;6(2):1-3

Clinical trials

1. **ADITI-1:** A Phase 1, Open Label, Dose Escalation, Multicenter, First-in-Human (FIH) Study Evaluating the Safety, PK and PD of Oral AUR112 in Patients with Relapsed Lymphoid Malignancies- **Primary Investigator**
2. A Multicenter, Single-arm, Open-label, Phase 4 Study to Evaluate the Safety and Efficacy of Brentuximab Vedotin plus Doxorubicin, Vinblastine, and Dacarbazine in Indian Patients with Untreated Stage 3/4 Classical Hodgkin Lymphoma.- **Primary Investigator**
3. **POLARGO:** A phase III, open-label, multicenter, randomized study evaluating the safety and efficacy of Polatuzumab Vedotin in combination with Rituximab plus Gemcitabine plus Oxaliplatin (R-GemOx) versus R-GemOx alone in patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma. **Co Investigator**
4. **ASHA-1:** A Phase 1, Open Label, Dose Escalation, Dose Expansion, Multicenter Study Evaluating the Safety, Pharmacokinetics and Pharmacodynamics of Oral AUR108 in Patients with Relapsed Advanced Lymphoma (AUR108-101) **Co Investigator**
5. **PACIFICA:** A Randomized, Controlled Phase 3 Study of Pacritinib Versus Physician's Choice in Patients with Primary Myelofibrosis, Post Polycythemia Vera Myelofibrosis, or Post Essential Thrombocythemia Myelofibrosis with Severe Thrombocytopenia (Platelet Counts <50,000/ μ L) **Co Investigator**
6. **IM048:** A Phase 3, Two-stage, Randomized, Multi-center, Controlled, Open-label Study Comparing Iberdomide Maintenance to Lenalidomide Maintenance Therapy after Autologous Stem Cell Transplantation (ASCT) in Participants with Newly Diagnosed Multiple Myeloma (NDMM) (EXCALIBER-Maintenance) **Co Investigator**
7. **Magnetism 7 :** A randomized, 2-arm, phase 3 study of elranatamab (pf-06863135) versus lenalidomide in patients with newly diagnosed multiple myeloma after undergoing autologous stem-cell transplantation . **Co Investigator**
8. **DARVIVA:** A Double-Blind, Randomized Clinical Study of the Efficacy and Safety of Monotherapy with BCD-264 and Darzalex[®] in Subjects with Relapsed and Refractory Multiple Myeloma. **Co Investigator**
9. **PRIME :** Effect of pomalidomide-bortezomib-dexamethasone induction on MRD status in patients with newly diagnosed multiple myeloma. **Co Investigator**
10. A Phase 1, Open Label, Dose Escalation, Dose Expansion, Multicenter, First in Human (FIH) Study Evaluating the Safety, Pharmacokinetics and Pharmacodynamics of Oral AUR107 in Patients with Relapsed Advanced Malignancies (SHAKTI-1). (**Co-Investigator**)

11. A Phase 1/2, Open Label, Multicenter Study to Evaluate the Efficacy and Safety of DRL-1801 in Patients with RRMM (SWASTH). **(Co-Investigator)**
12. An Open Label, Multicenter, Phase IV Study of Teclistamab to Evaluate its Safety in Indian Participants with Relapsed and Refractory Multiple Myeloma who have previously received at least 3 prior lines of therapy including an Immunomodulatory agent, a Proteasome Inhibitor and an Anti- CD38 antibody and have demonstrated disease progression on the last therapy. **(Co-Investigator)**
13. A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study Comparing the Efficacy and Safety of Golcadomide Plus R-CHOP Chemotherapy vs Placebo Plus R-CHOP Chemotherapy in Participants with Previously Untreated High-risk Large B-cell Lymphoma (GOLSEEK-1) **(Co-Investigator)**
14. A Phase 3, Two-stage, Randomized, Multi-centre, Controlled, Open-label Study Comparing Iberdomide Maintenance to Lenalidomide Maintenance Therapy after Autologous Stem Cell Transplantation (ASCT) in Participants with Newly Diagnosed Multiple Myeloma (NDMM). **(Co-Investigator)**

Membership

1. Indian Society of Hematology & Blood transfusion (ISHBT)
2. American Society of Hematology (ASH)
3. European Society Of Medical Oncology (ESMO)
4. Indian Myeloam Academic Groupe (IMAGe)
5. International Myeloma Society (IMS)
6. International Society of Amyloidosis (ISA)
7. European Hematology Association (EHA)

ORCID ID:

<https://orcid.org/0000-0003-4486-5340>